Aardvark Therapeutics, Inc. AARD

US Pharmaceuticals

$1.39 ▲ +2.96% (+$0.04)

📅 Earnings This Week

Open $1.33

Prev Close $1.35

Day Range $1.29 – $1.44

52W Range $0.93 – $16.60

Market Cap $29.54M

Beta 4.75

EPS (TTM) $-3.21

📋 Company Profile

Industry	Pharmaceuticals
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2025-02-13
Shares Out.	21,880,000
Website	aardvarktherapeutics.com ↗
Phone	18009279800
Employees	28
Revenue	$0
Gross Profit	$0
Net Income	-$14.4M
Free Cash Flow	-$69.4M
Total Assets	$81.5M
Total Liabilities	$6.7M
Equity	$74.8M

About Aardvark Therapeutics, Inc.

Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

Aardvark Therapeutics, Inc. is a publicly traded company under the ticker symbol AARD on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.